-
Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China
Author: Fei, Zhengyang; Rui, Mingjun; Wang, Yingcheng; Ma, Aixia
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2023; Vol. 23, Issue 1, pp. 79-87. DOI: 10.1080/14737167.2023.2144837
-
Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China
Author: Zheng, Zhiwei; Fang, Ling; Cai, Hongfu; Zhu, Huide
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2023.2206570
-
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China
Author: Shang, Fangjian; Zhang, Boyuan; Kang, Shuo
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2023; Vol. 23, Issue 3, pp. 337-343. DOI: 10.1080/14737167.2023.2170877
-
Comparing measurement properties of EQ-5D and SF-6D in East and South-East Asian populations: a scoping review
Author: Zhang, Aixue; Mao, Zhuxin; Wang, Zitong; Wu, Jing; Luo, Nan; Wang, Pei
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2023.2189590
